Abstract-β-Arrestin (βarr)-1 and β-arrestin-2 (βarrs) are universal G-protein-coupled receptor adapter proteins that negatively regulate cardiac β-adrenergic receptor (βAR) function via βAR desensitization and downregulation. In addition, they mediate G-protein-independent βAR signaling, which might be beneficial, for example, antiapoptotic, for the heart. However, the specific role(s) of each βarr isoform in cardiac βAR dysfunction, the molecular hallmark of chronic heart failure (HF), remains unknown. Furthermore, adrenal βarr1 exacerbates HF by chronically enhancing adrenal production and hence circulating levels of aldosterone and catecholamines. Herein, we sought to delineate specific roles of βarr1 in post-myocardial infarction (MI) HF by testing the effects of βarr1 genetic deletion on normal and post-MI cardiac function and morphology. We studied βarr1 knockout (βarr1KO) mice alongside wild-type controls under normal conditions and after surgical MI. Normal (sham-operated) βarr1KO mice display enhanced βAR-dependent contractility and post-MI βarr1KO mice enhanced overall cardiac function (and βAR-dependent contractility) compared with wild type. Post-MI βarr1KO mice also show increased survival and decreased cardiac infarct size, apoptosis, and adverse remodeling, as well as circulating catecholamines and aldosterone, compared with post-MI wild type. The underlying mechanisms, on one hand, improved cardiac βAR signaling and function, as evidenced by increased βAR density and procontractile signaling, via reduced cardiac βAR desensitization because of cardiac βarr1 absence, and, on the other hand, decreased production leading to lower circulating levels of catecholamines and aldosterone because of adrenal βarr1 absence. Thus, βarr1, via both cardiac and adrenal effects, is detrimental for cardiac structure and function In addition, the βAR-bound βarrs have been shown to elicit a second wave of G-protein-independent signals, some of which might be beneficial for the failing heart, for example, extracellular signal-regulated kinase activation and epidermal growth factor receptor (EGFR) transactivation, both of which can promote cardiac cell survival, proliferation, etc.
D espite recent advances in its prevention and management, heart disease, such as hypertension and post-myocardial infarction (MI) heart failure (HF), remains the leading cause of death in the Western world and new treatments are needed. 1 The molecular hallmark in chronic HF is cardiac β-adrenergic receptor (βAR) dysfunction because of increased receptor desensitization and downregulation. [2] [3] [4] [5] [6] βARs belong to the superfamily of G-protein-coupled receptors (GPCRs), which, on agonist binding, activate the G s protein-adenylyl cyclasecyclic adenosine monophosphate (cAMP)-protein kinase A signaling pathway leading to increased inotropy and chronotropy in the heart. 2 In chronic HF, however, there is a selective downregulation of cardiac β 1 ARs and significant functional desensitization (G protein uncoupling) of the remaining membrane β 1 ARs and β 2 ARs, which dramatically diminish cardiac adrenergic and inotropic reserves. [3] [4] [5] [6] These processes are mediated at the molecular level by the β-arrestins (βarrs), which exist in 2 distinct isoforms (βarr1 and βarr2, also known as arrestin-2 and arrestin-3, respectively) in mammals and are abundantly expressed in the heart. 7-9 βarrs bind agonistactivated cardiac βARs, terminating their G-protein-mediated signaling and targeting them for internalization, after receptor phosphorylation by GPCR kinase (GRK)-2 (mainly), the main cardiac GRK that is significantly elevated in HF. 2, [8] [9] [10] [11] [12] [13] [14] [15] [16] Consistent with their crucial role in cardiac βAR desensitization, βarr1 knockout (KO) mice display enhanced cardiac contractile responses to isoproterenol (a standard βAR full agonist) stimulation in vivo.
In addition, the βAR-bound βarrs have been shown to elicit a second wave of G-protein-independent signals, some of which might be beneficial for the failing heart, for example, extracellular signal-regulated kinase activation and epidermal growth factor receptor (EGFR) transactivation, both of which can promote cardiac cell survival, proliferation, etc. [18] [19] [20] [21] However, the actions of the 2 βarrs in vivo are rarely complementary; in fact, they might even oppose each other's effects in certain tissues/ organs, including in the cardiovascular system (eg, vascular smooth muscle cells and cardiomyocytes). 22, 23 With regard to the heart, the exact role of each βarr in cardiac βAR desensitization or G-protein-independent signaling is not presently known.
The physiological hallmark of chronic HF is the sustained hyperactivity of several neurohormonal systems, in particular the sympathetic nervous and the renin-angiotensin-aldosterone systems, accompanied by elevated circulating levels of the catecholamines (CAs) norepinephrine and epinephrine and of aldosterone, respectively. 9, 14, 15 All these circulating hormones exert detrimental effects on the failing heart, leading both to diminished function and to accelerated and aggravated adverse remodeling in chronic HF. 24, 25 The main source of these circulating hormones is the adrenal gland and we have shown in previous studies that βarr1, in particular, is a crucial mediator of adrenocortical aldosterone production, 26, 27 as well as of adrenomedullary CA production (acting in concert with adrenal GRK2), 28-30 both normally and in post-MI HF in vivo. Given that the specific roles of cardiac βarr1 in βAR (dys) function and signaling in HF have never been investigated and also the crucial role this protein plays in the adrenals in elevating the neurohormonal burden of the failing heart, we sought to investigate, in the present study, the effects of its genetic deletion on cardiac function, both normally and in post-MI HF. To study the (patho)physiological role(s) specifically of this βarr isoform in vivo, we took advantage of the available βarr1KO mouse model 17 and studied these mice alongside age-matched wild-type (WT) controls (of note, the double βarr1/2 KO mice are embryonic lethal). 9 We found that the absence of βarr1 from the heart and the adrenals leads to significantly elevated cardiac function in post-MI HF, accompanied by improved adverse remodeling, reduced neurohormonal activation, and better cardiac βAR signaling and function.
Materials and Methods

Experimental Animals and Surgical Procedures
The animals in this study were handled according to the animal welfare regulations and protocols approved by the authors' institutional review boards. An expanded Materials and Methods section is available in the online-only Data Supplement, which includes detailed methods on the following: animals and surgical procedures, echocardiography and hemodynamics, ELISA measurements of hormones and cytokines, infarct size measurements, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and Masson-Trichrome staining, real-time polymerase chain reaction, βAR density, cAMP and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) activity measurements, and Western blotting. 
Statistical Analyses
Results
Cardiac Function of Normal and Post-MI βarr1KO Mice
To investigate the impact on cardiac function of the genetic deletion exclusively of βarr1, we used the available global βarr1KO mouse model ( Figure S1 in the online-only Data Supplement). These mice breed normally, without any gross abnormalities and present no overt cardiovascular or other phenotype. 17 To induce HF, 3-month-old male mice underwent surgical MI and were studied alongside age-matched male WT mice. We first examined the cardiac function parameters of these mice, both in sham and in post-MI groups. Echocardiography revealed that, although similar between the sham groups (a finding consistent with the results of a previous study on these mice), 17 (basal) ejection fraction was severely diminished in WT mice at 4 weeks after MI, as expected, but significantly higher in the post-MI βarr1KO mice at the same time point ( Figure 1A ; Table S1 ). Consistent with these findings, on in vivo catheterization for hemodynamic measurements, post-MI βarr1KO mice also show significantly enhanced cardiac contractility, both basally and in response to isoproterenol stimulation, compared with post-MI WT mice ( Figure 1B ; Table S1 ) although left ventricular end-systolic and end-diastolic pressures are (Table S1 ). Notably, isoproterenol-induced contractility is elevated also in sham (normal) βarr1KO mice compared with sham WT ( Figure 1B ; Table S1 ), which is again consistent with the results of a previous study on these mice. 17 Taken together, these findings strongly indicate that cardiac βarr1 is a major negative regulator of βAR-dependent contractility in vivo and that its absence leads to significant attenuation of cardiac dysfunction after MI.
Survival and Neurohormonal Status of Post-MI βarr1KO Mice
Next, we sought to further examine the phenotype of the post-MI βarr1KO mice. Kaplan-Meier survival curves indicated a markedly lower (overall) mortality of the post-MI βarr1KO mice compared with post-MI WT controls (P=0.012; Figure 2A ). This was accompanied by significantly reduced elevations in the plasma circulating levels of the CAs norepinephrine and epinephrine in post-MI βarr1KO mice compared with post-MI WT ( Figure 2B ), indicative of reduced overall sympathetic activation in post-MI HF βarr1KO mice. As for the other major cardiotoxic hormone, aldosterone, post-MI βarr1KO mice, remarkably, failed to exhibit any hyperaldosteronism (ie, elevation of circulating aldosterone levels) whatsoever, in marked contrast to post-MI WTs, which, as expected, display severe hyperaldosteronism ( Figure 2C ). This finding strongly corroborates the essential role of adrenal βarr1 in post-MI HF-associated hyperaldosteronism as we have previously reported. 26, 27 Finally, and consistent with these effects on circulating levels of CAs and aldosterone, post-MI βarr1KO mice also display significantly lower mean arterial blood pressure (125±4 mm Hg) than post-MI WT (141±5 mm Hg) at 4 weeks after MI (P<0.05; n=5).
Cardiac Apoptosis, Dilatation, and Infarct Size in Post-MI βarr1KO Mice
The increased survival of the post-MI βarr1KO mice prompted us to investigate the cardiac apoptosis in these mice. Cardiac cellular apoptosis, as measured with the TUNEL assay in the hearts of the post-MI mice, was found significantly reduced in βarr1KO mice compared with WT mice at 24 hours after MI, which is consistent with the Kaplan-Meier survival results ( Figure 3A ). In addition, cardiac dilatation was also decreased in the βarr1KO mice compared with WT controls at 4 weeks after MI ( Figure 3B ; Table S1 ), and, importantly, infarct size was also significantly reduced in the βarr1KO hearts compared with control WT hearts at the same post-MI time point (4 weeks; Figure  3C and 3D). To exclude the possibility that differences in the extent of the initial injury inflicted by our surgical MI method on the 2 lines might have been responsible for this result, infarct size at 24 hours after MI was also measured and found indistinguishable between the 2 groups ( Figure S2A and S2B) . Taken together, these results indicate that post-MI βarr1KO hearts have decreased apoptosis, dilatation, and infarct size, which might underlie their favorable overall survival phenotype. 
Cardiac βAR Density, Signaling, and Function in Post-MI βarr1KO Mice
In an effort to dissect the molecular mechanisms underlying the dramatic effect of the absence of βarr1 on cardiac contractile function, we also investigated several aspects of cardiac βAR signaling and function in the 2 post-MI groups. Consistent with the phenotypic and functional data, total βAR density in the post-MI βarr1KO hearts was significantly higher compared with post-MI WT hearts, which display marked βAR downregulation after MI, as expected ( Figure 5A ). This attenuated βAR downregulation in post-MI βarr1KO hearts was accompanied by preserved total cAMP levels, again in sharp contrast with the WT hearts whose cAMP content is dramatically diminished after MI ( Figure 5B ). Given that cAMP is the most critical mediator of cardiac βAR procontractile signaling, 2,15 this result strongly indicates that the absence of cardiac βarr1 is sufficient to restore βAR-dependent contractility in post-MI HF. Another important component of the cardiac contractile machinery regulated by βARs is SERCA-2a. 31 SERCA activity was also found to be significantly increased in post-MI βarr1KO hearts compared with post-MI WT hearts ( Figure 5C ), thus providing another line of evidence for the increased contractile function of post-MI βarr1KO hearts. Of note, however, cardiac SERCA activity of βarr1KO mice seems elevated also in the normal (sham) groups ( Figure 5C ), indicating that cardiac βarr1 might affect the cardiac contractile machinery even under normal conditions (no HF). Finally, because cardiac βarrs, and in particular βarr2, have been shown to mediate EGFR transactivation from the β 1 AR upon the latter's phosphorylation by GRK5, an effect that is considered antiapoptotic in the heart, 18 we also examined levels of EGFR transactivation in the post-MI hearts of βarr1KO mice and WT after acute stimulation with isoproterenol in the presence of ICI-118,551 (a β 2 AR-selective antagonist) in vivo (to activate the β 1 ARs only). Western blotting for phospho-Tyr845-EGFR (active EGFR) in cardiac extracts from these mice revealed significantly elevated EGFR transactivation in βarr1KO hearts compared with WT hearts at 24 hours after MI (and also in sham hearts; Figure 5D and 5E), suggesting that cardiac βarr1 inhibits (rather than promotes) this β 1 AR-induced EGFR transactivation in the heart. Finally, in an effort to better dissect the relative contributions of cardiac versus adrenal βarr1 on the observed phenotypes of the mice of the study, we overexpressed the known βarr1 inhibitor mini-gene βarr1ct 27 specifically in the hearts of post-MI WT mice, to inhibit cardiac (only) βarr1 in vivo, and studied these hearts alongside control post-MI WT hearts receiving adenovirus encoding for green fluorescent protein at the time of MI. As shown in Figure S4 , cardiac βarr1 inhibition with βarr1ct led to significant improvements in cardiac βAR density ( Figure S4A ) and cAMP accumulation ( Figure S4B ) at 4 weeks after MI, indicating improved cardiac adrenergic and inotropic reserves, as expected; however, no significant changes in circulating CAs of the post-MI WT mice were observed with cardiac βarr1ct at 4 weeks after MI (Figure S4C ), indicating that CA production/ secretion is mediated by adrenal (rather than cardiac) βarr1. 
Discussion
βarr1 (and to a lesser extent βarr2) is abundantly expressed throughout the cardiovascular system [7] [8] [9] and regulates the majority of cardiovascular GPCRs, including cardiac βARs, cardiac and adrenocortical angiotensin II type 1 receptors, adrenal and central sympathetic nervous system α 2 ARs, etc. 9, 32, 33 The importance of βarrs in cardiovascular (and other systems) biology is evidenced by the fact that the double βarr1/2 KO mouse is embryonic lethal. 32, 33 Their actions on the heart have been attributed to both their functions as receptor desensitizers/internalizers and as G-protein-independent signal transducers. 9, 32 However, and especially for their latter function, the exact in vivo roles of each cardiac βarr isoform in GPCR-dependent signal transduction are currently unknown. In the present study, we were able to delineate the cardiovascular phenotype of βarr1KO mice in post-MI HF, along with its associated underlying molecular signaling mechanisms. Specifically, we found that the absence of βarr1 from the heart leads to significantly better overall cardiac function in post-MI HF, dramatically increases cardiac βAR-dependent cardiac function both physiologically and in post-MI HF, and significantly attenuates adverse remodeling, apoptosis, inflammation, and infarct size, leading to improved overall survival post-MI. At the same time, the absence of βarr1 from the adrenal gland leads to a dramatically improved neurohormonal profile of the failing post-MI heart, with reduced circulating CA and aldosterone levels. Finally, cardiac βAR signaling and function are dramatically elevated in the post-MI βarr1KO mice, translating into markedly improved cardiac adrenergic and inotropic reserves.
Thus, βarr1 seems to be the single most important negative regulator of βAR-dependent procontractile signaling and function, via the classical processes of desensitization and downregulation of the cardiomyocyte βAR content, and its absence results in dramatically elevated βAR-dependent contractility, both normally and after MI, and in almost restored functional βAR number and cAMP-mediated signaling post-MI, that is, in dramatically improved β-adrenergic and inotropic reserves of the failing heart. Consistent with this, cardiac SERCA activity is also markedly elevated in post-MI βarr1KO mice compared with control WT mice. Of note however, SERCA activity is also significantly elevated in normal (sham) βarr1KO mice, suggesting that the effects of cardiac βarr1 on SERCA activity extend beyond (merely) βAR desensitization. Indeed, current investigations suggest that cardiac βarr2 directly interacts with SERCA-2a, promoting its SUMOylation and increasing its activity, 34 and that this is actually opposed by βarr1 (A. Lymperopoulos, unpublished data). However, βarr2 seems unable to compensate for the absence of βarr1 for any of these effects in vivo (and it is not compensatively upregulated, Figure 5 . A, β-Adrenergic receptor (βAR) density in cardiac plasma membranes of sham-operated (Sham) or of 4-week post-myocardial infarction (MI) β-arrestin-1 knockout (βarr1KO) and wild-type (WT) mice. *P<0.05 vs all other groups; n=5 hearts/group. B, Steadystate total cAMP levels in cardiac homogenates purified from these mice. *P<0.05 vs all other groups; n=5 hearts/group. C, Cardiac sarco(endo)plasmic reticulum Ca 2+ -ATPase activity measured in membrane homogenates from the hearts of these mice. *P<0.05 vs WT Sham; **P<0.05 vs WT MI; n=5 hearts/group. D and E, Cardiac epidermal growth factor receptor (EGFR) transactivation in these mice. Representative Western blots in total cardiac protein extracts for phospho-Tyr845-EGFR or total EGFR (loading control) are shown in D and their densitometric measurement in E. Relative EGFR transactivation was calculated by comparing the ratios of phospho-EGFR to total EGFR for each sample. *P<0.05 vs either WT; **P<0.05 vs KO Sham; n=5 hearts/group. by guest on April 19, 2017 http://hyper.ahajournals.org/ Downloaded from February 2014 either; data not shown 17 ). Taken together, these phenotypic findings strongly suggest that the βarr1 isoform is the salient βarr responsible for βAR desensitization and downregulation in the heart (Figure 6 ), processes whose dramatic elevation constitutes a molecular hallmark of chronic HF. 2, 3, 5 Therefore, prevention of the interaction of βarr1 with cardiac βARs, which is achieved (indirectly) via cardiac GRK2 inhibition with βARKct (β-adrenergic receptor kinase C-terminus) for instance, 13, 15, 35 might be beneficial as a positive inotropic therapy for HF ( Figure 6 ).
It is now well known and documented that βarrs, in addition to the original biological role ascribed to them as terminators of G-protein-dependent signaling by GPCRs, can also serve as signal transducers in their own right independently of G proteins. 32, 33 Indeed, specifically in the heart, βarrs have been shown to mediate beneficial, antiapoptotic, and proliferationpromoting signals from the β 1 AR (upon its phosphorylation by GRK5 and not GRK2 though) and from the mechanical stretch-activated angiotensin II type 1 receptor via EGFR transactivation and subsequent extracellular signal-regulated kinase phosphorylation/activation. 18, 36 In addition, they might even mediate procontractile signaling from the angiotensin II type 1 receptor in cardiac myocytes, an effect ascribed to βarr2 and presumably inhibited by GRK2 and βarr1. 23 We found that β 1 AR-induced EGFR transactivation is significantly elevated in βarr1KO hearts in vivo, both in normal (sham) conditions and (even more so) in post-MI HF, consistent with the apoptotic phenotype of the βarr1KO hearts in vivo. This strongly suggests that cardiac βarr2 normally mediates this beneficial, antiapoptotic β 1 AR-dependent EGFR transactivation, whereas cardiac βarr1 opposes this signaling mechanism ( Figure 6 ). Of course, studies in βarr2KO mice are warranted to further validate this scenario. Another important aspect of HF pathophysiology, in which the 2 βarr isoforms might exert differential or even opposing effects, is peri-infarct area neoangiogenesis 37 ; in fact, given the difference observed in infarct size at 4 weeks after MI ( Figure 3C and 3D) , this is quite likely and certainly warrants further investigation in the future.
Finally, the neurohormonal profile of the post-MI βarr1KO mice confirms the essential roles of adrenal βarr1 in (1) chronically elevated CA secretion in post-MI HF (via chronic desensitization/downregulation of the sympatho-inhibitory α 2 ARs in the chromaffin cells of the adrenal medulla; Figure 6 ), and (2) post-MI HF-associated hyperaldosteronism (via increased angiotensin II-dependent aldosterone synthesis and secretion in adrenocortical zona glomerulosa cells; Figure  6 ), which we have uncovered during the past several years. [26] [27] [28] [29] [30] Admittedly, the biggest limitation of the present study is the use of a global KO model that precludes any safe conclusions on the relative contributions of adrenal versus cardiac βarr1 on the observed phenotypic effects of the post-MI βarr1KO mice. Only development of tissue-specific KO mice can provide definitive answers to this important question. However, our data on post-MI WT mice having cardiac-specific blockade of βarr1 courtesy of cardiac-specific βarr1ct overexpression strongly suggest that cardiac βarr1 absence is responsible for the observed improvements in the adrenergic and inotropic reserves of the post-MI βarr1KO mice, whereas their vastly improved neurohormonal profile (ie, lower circulating CA levels and complete absence of hyperaldosteronism) is (mainly) because of βarr1 absence from the adrenal glands. Given the extensive cross-talk between the 2 organs (heart-adrenals) and that aldosterone and catecholamines can be produced also in the heart per se however, 38, 39 drawing of these conclusions warrants extreme caution. Nevertheless, all of the above findings are clinically important: we report for the first time that βarr1 is the βarr isoform mainly (if not exclusively) responsible for cardiac βAR desensitization and downregulation in vivo, a hallmark abnormality in chronic HF. In addition, βarr1 promotes elevation of the neurohormonal burden of the failing heart through its actions in the adrenal gland and seems to oppose several beneficial signaling effects of its counterpart, βarr2, in the myocardium, such as EGFR transactivation and extracellular signal-regulated kinase signaling, which lead to inhibition of apoptosis and inflammation and to promotion of cardiac survival. Thus, βarr1 removal from both the heart and the adrenals results in significantly improved cardiac function, structural remodeling, β-adrenergic and inotropic reserves, reduced neurohormonal burden, and increased cardiac and overall survival in post-MI HF. These findings strongly suggest that inhibition of βarr1 activity toward βARs in the heart and βarr1 blockade in the adrenals, either directly (with a pharmacological βarr1-specific inhibitor or via small interfering RNA knockdown) or indirectly (eg, via blockade of GRK2, which promotes association of βarr1 with cardiac βARs) might be a viable therapeutic strategy for chronic post-MI HF treatment, with the potential also of complementing or enhancing the benefits of β-blocker therapy, which is hampered by the adverse effect of negative inotropy.
Perspectives
The present study reports for the first time that cardiac βarr1 is the βarr isoform responsible for cardiac βAR desensitization and downregulation in vivo, a hallmark molecular abnormality in chronic HF. In addition, adrenal βarr1 promotes elevation of the neurohormonal burden of the failing heart by mediating CA secretion and aldosterone synthesis and secretion in the adrenal medulla and cortex, respectively. Finally, βarr1 seems to oppose several beneficial signaling effects of its counterpart, βarr2, in the myocardium, such as EGFR transactivation and extracellular signal-regulated kinase signaling, which lead to inhibition of apoptosis and inflammation and to promotion of cardiac survival. Thus, βarr1 removal from both the heart and the adrenals results in significantly improved cardiac function, halted adverse remodeling, elevated β-adrenergic and inotropic reserves, reduced neurohormonal burden, and increased cardiac and overall survival in post-MI HF. These findings strongly suggest that inhibition of βarr1 activity toward βARs in the heart and βarr1 blockade in the adrenals, either directly (with a pharmacological βarr1-specific inhibitor or via small interfering RNA knockdown) or indirectly (eg, via blockade of GRK2, which promotes association of βarr1 with receptors) might be a viable therapeutic strategy for chronic post-MI HF treatment.
What Is New?
• βarrestin (βarr1; rather than βarr2) is the βarr isoform responsible for β-adrenergic receptor desensitization and downregulation in vivo in the heart, a hallmark molecular abnormality in chronic heart failure.
• βarr1 in the adrenals is absolutely essential for post-myocardial infarction hyperaldosteronism and catecholamine elevation in vivo, thereby heightening the neurohormonal burden of the failing heart.
• Cardiac βarr1 also counters some beneficial effects of βarr2 in the myocardium, for example, antiapoptosis and suppression of inflammation.
What Is Relevant?
• Adrenal βarr1 can promote hyperaldosteronism and sympathetic hyperactivity, 2 neurohormonal mechanisms that contribute significantly to the development of hypertension and heart failure.
• Pharmacological or genetic βarr1 inhibition in vivo, at least in the adrenals and in the heart, might be a valid antihypertensive and anti-heart failure treatment strategy.
